Voriconazole: A new triazole antifungal

Annals of Pharmacotherapy

Volumn 34, Issue 9, 2000, Pages 1032-1043

  Sabo, J A ^a   Abdel Rahman, S M ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Antifungal; Triazole; UK 109,496; Voriconazole

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CROSS RESISTANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; MYCOSIS; PRIORITY JOURNAL; VISUAL DISORDER;

EID: 0033848786     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19237     Document Type: Article

References (98)

1. Antifungal agents: An overview. PART I
2. History of antifungals
3. Medical mycology, antifungal chemotherapy and fungal vaccines
4. Renal effects of amphotericin B lipid complex
5. The epidemiology and prevention of invasive aspergillosis
6. Candidemia at selected Canadian sites: Results from the fungal disease registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society
7. Antifungal agents in the 1990s. Current status and future developments
8. Clinical pharmacokinetics of fluconazole
9. Optimization of oral antifungal therapy
10. Itraconazole: Managing mycotic complications in immuno-compromised patients
11. Current antifungal therapy of human mycoses
12. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
13. In vitro evaluation of voriconazole against some clinically important fungi
14. In vitro studies of two triazole antifungal agents (UK-109,496) and fluconazole against Candida species
15. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species
16. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 400 clinical isolates of Candida spp
17. In vitro activity of voriconazole against Candida species
18. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species
19. Organism-dependent fungicidal activities of azoles
20. Use of voriconazole in treatment of Scedosporium apiospermum infection: Case report
21. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infections. Subcommittee on antifungal susceptibility testing of national committee for clinical laboratory standards
22. Invasive aspergillosis caused by Aspergillus ustus: Case report and review
23. In vitro susceptibility of dermatophytes to antifungal drugs: A comparison of two methods
24. In vitro susceptibility of dermatophytes to antifungal drugs
25. Pharmacokinetics of newer drugs in patients with renal impairment
26. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses
27. Optimization of itraconazole therapy using target drug concentrations
28. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS
29. The triazole antifungal agents: A review of itraconazole and fluconazole
30. Itraconazole. A review of pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses
31. Itraconazole and fluconazole: New drugs for deep fungal infections
32. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects
33. Food interaction and steady state pharmacokinetics of itraconazole oral solution in healthy volunteers
34. Pharmacokinetics of itraconazole following oral administration to normal volunteers
35. Fluconazole concentrations in human saliva after multiple doses
36. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
37. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
38. Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B
39. The influence of some antifungal drugs on in vitro adherence of Candida albicans to human buccal epithelial cells
40. Effects of sub-inhibitory concentrations of ketoconazole on in vitro adherence of Candida albicans to vaginal epithelial cells
41. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells
42. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment on infections in nonneutropenic patients
43. A comparative review of colony-stimulating factors
44. Emerging applications of recombinant human granulocyte-macrophage colony stimulating factor
45. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
46. Comparison of the in vitro activity of voriconazole, itraconazole, and amphotericin B against clinical isolates of Aspergillus fumigatus
47. Activity of voriconazole combined with neutrophils or monocytes against A. fumigatus: Effects of granulocytes, colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
48. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
49. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens
50. Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: A culture and microscopic study
51. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates
52. Voriconazole antifungal
53. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia
54. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease
55. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease
56. The search for new triazole antifungal agents
57. Investigators seeking new ways to stem rising tide of resistant fungi
58. Ketoconazole and candidiasis: A controlled study
59. Overview of studies of fluconazole in oropharyngeal candidiasis
60. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients
61. Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody positive group of patients
62. Skull base osteitis following fungal sinusitis
63. The future of antifungal therapy
64. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
65. Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: Cure with voriconazole
66. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
67. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single center experience of 133 episodes in 116 patients
68. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
69. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria
70. Therapeutic outcome in invasive aspergillosis
71. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
72. Lymphocutaneous infection due to Scedosporium apiospermum
73. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor
74. Fungal arthritis due to Pseudallescheria boydii (Scedosporium apiospermum)
75. Endocarditis and hip arthritis associated with Scedosporium inflatum
76. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium prolificans Spanish Study Group
77. Scedosporium inflatum infection in immunocompromised haematological patients
78. Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata
79. Mechanism of fluconazole resistance in Candida krusei
80. Fluconazole resistance in Candida glabrata
81. Resistance of Candida albicans to azole antifungal agents